blank
blank

Breaking barriers in cell and gene therapy: advancing ATMPs through innovation and collaboration

1:1
Effective collaboration between industry, academia, and patient organizations is essential to advance standardized platform technologies. A recent example is the newly launched European Rare Diseases Research Alliance (ERDERA).

In recent years, a slew of advanced therapy medicinal products (ATMPs), particularly cell and gene therapies, have demonstrated the transformative power of these therapies. CAR-T cell therapy, for example, has revolutionized the field in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM). CAR-T cell application in solid tumors, however, remains elusive due to a variety of challenges in the biology. This not withstanding, results published in 2024 brought renewed optimism for the use of CAR-Ts in solid tumors, by showing that targeting two brain tumor-associated proteins instead of one showed promise
as a strategy for reducing tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer.

Acces this publication (pdf)
CELL & GENE THERAPY INSIGHTS

Year of publication

2025

Source

Science DIrect

Link to cite

Acces to Link >

Author

Anton Ussi, Toni Andreu, Florence Bietrix, and David Morrow

You might also be interested in

Radka Kaneva and Petia Stratieva, Sofia, March 2026

“National Mirror Groups are essentially a bridge — bringing European developments, standards and opportunities to clinicians and researchers.”

ERDERA interviews Prof. Radka Kaneva and Dr Petia Stratieva, two leading members of Bulgaria’s National Mirror Group (NMG), to explore how the country is working to align its rare disease ecosystem with European developments.
Gdańsk - Medical University of Gdańsk

From Hyderabad to Gdansk: collaborative diagnostic efforts that bridge research and clinical practice to shorten patients’ path to answers

ERDERA joins the Wilhelm Foundation and the Gdansk Medical University and Clinical Centre to strengthen phenotype‑led diagnosis for people living with undiagnosed conditions
Captura de pantalla 2026-04-08 142004

Advancement of Treatments for Rare Diseases

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.

ERDERA's

search form